<SEC-DOCUMENT>0001193125-12-386632.txt : 20120910
<SEC-HEADER>0001193125-12-386632.hdr.sgml : 20120910
<ACCEPTANCE-DATETIME>20120910162559
ACCESSION NUMBER:		0001193125-12-386632
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120910
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120910
DATE AS OF CHANGE:		20120910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		121083446

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d409442d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>September&nbsp;10, 2012 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. PHARMA,
INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code:&nbsp;(650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General
Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01&nbsp;Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;10, 2012, A.P. Pharma, Inc. (the &#147;Company&#148;) announced the appointment of Thomas Pitler, Ph.D. as Vice President of Business Development. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01&nbsp;Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Document Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on September&nbsp;10, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. PHARMA, INC.</FONT></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: September&nbsp;10, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d409442dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g409442g81b21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDWOOD
CITY, Calif. &#150; September&nbsp;10, 2012 &#150; A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Thomas Pitler, Ph.D. as vice president of business development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;Tom has extensive business development experience in establishing long-term collaborations around platform technologies,&#148; said John B. Whelan, A.P. Pharma&#146;s president and chief executive
officer. &#147;As we look toward the potential commercialization of APF530, we are focusing on opportunities that support not just the APF530 program but also programs emerging from our proprietary Biochronomer&#153; technology. We are thrilled to
have Tom join us during this pivotal time and look forward to his contributions to the A.P. Pharma executive team.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most recently,
Dr.&nbsp;Pitler was vice president of business development at Chimerix, where he was responsible for the company&#146;s interactions with potential partners, leading the due diligence and negotiations process around the licensing of clinical stage
programs, preclinical assets and underlying technology. Earlier, Dr.&nbsp;Pitler held the position of senior vice president, chief business and financial officer at Neurogen, Inc. (acquired by Ligand Pharmaceuticals).&nbsp;At Neurogen,
Dr.&nbsp;Pitler established research and development collaborations with pharmaceuticals companies, including Merck and Aventis. Dr.&nbsp;Pitler was also a Research Assistant Professor at the University of Maryland School of Medicine and has held
other academic positions.&nbsp;He received a B.A. in Biology and a Ph.D. in Physiology from Wake Forest University.</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer&#153; polymer-based drug delivery
platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one
or two weeks. The Company&#146;s lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P. Pharma received a Complete Response Letter to its APF530 New Drug
Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration in September 2012. For further information, please visit the Company&#146;s web site at www.appharma.com. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news
release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>- more - </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B>Page 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><I>of Business Development</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and uncertainties, including uncertainties associated with the potential approval of APF530 and the potential timing for such approval, if approved at all, as well as risks relating to capital
resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings with the Securities
and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: (646)&nbsp;597-6979
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: mrice@lifesciadvisors.com </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President and Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#035;&#035;&#035; </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g409442g81b21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g409442g81b21.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.P"U`P$1``(1`0,1`?_$`+D```$#!0$!````````
M```````("0H!`@0&!P,%`0`!!`,!`0```````````````08'"`(#!0D$$```
M!@$#`@0"!P4&!`<````!`@,$!08'`!$((1(Q$Q0)(C)!46$C%18*@9%"-!=Q
MH;'A4C7PT?$S8F,D1#8G.!$``0(%`P$&`P4%!P('`````1$"``,$!08A$@<Q
M05%A(A,(<8$RD:%"%!6QP5(C%M'Q<H(S0Q=B)/#ADG.#-!C_V@`,`P$``A$#
M$0`_`)_&B"#1!!H@C%<NDFZ9U51*1-(ISJG.<B9$DDP$5%5%#F*1-(A>HF,(
M``>(Z4`N.T*7'0`!5/=&#W-EM,Q[FME-"N<X@`#OUAJWDY[Q?";C<XD:V>\+
M9;OL>==!:FXE(C8S,GJ'<`H3-G\]O6(HQ#%^,HNE%2[?]L1#;4Q81P-R#EX;
M.ET;J*WDZS*@%OE_B:UVKM-4TB"L_P#<)QQA0,EU0VON#=1+D%?,.@<YJ@:_
M&&;,E?J/,LR2[A'$7'*A5J/$5`:2.1+1/VR2$H"()JK1U>3K<:D<Y=A[//6V
M^OZ=3_9_:):9R?U!=9LP=TEH8$^8<5^<5TO'O4O$QI;8K1*8[OF$N_86Z?*.
M-M/U#7-1)RD9>@\>W#8AB"LW+6+JU%<H"!CD*J6[*&2[PZ;[#MXZ<@]G7&SG
M.]"ON+)@&A<X(J?X!#5__9'(K"V;.HJ`RR=0&E4_]9/W0Y-Q&_4!XJRK:(>@
M\EZ"3!<U,N4(V.OD1,KV#&JD@Z5(DV3G@>MFTS4D5E3=OJ%P<-DQ$!45(7<P
M0OR![8;UCM.^YXY5_GZ20KC*``F;4ZJ/J*]B")OX[]V=AR:OE6?)Z7\E.G$-
M$P.)E[CT!54!ZJL2'&ZS=XW;NVZR3ALX31<-W#94BZ"Z*Q2J(KMUDQ,15%9,
MP"4Q1$IBCN&JPO9,9,28TLGM)!:>NA0J.\?=%MW.D5$ELT%KI3D+'-U4%"$(
M70Q]'1&^#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!%IA``'KUV'Z
MM_#2.!<TM:4<1U[O&`E`O5(\A5*40`Q]M^@=W:'7;P#PTFPME`/=J/Q:?W0K
M9;W*\+J.G="3^6?,[!G#3'SB^9DMA&*KLCA*ITZ*%![<KI)H(@<(ZMP_<518
MI1,`K.51(V;E'=0Y>@"\<%P7(N0[F;5C<B9-#3_,FIY9;3^)40IV=YTAB9YR
M/C/'-J%PR.?+EU!7TY2^:8[L"*H'CI\XAB\WO=HY,<R'\K76\TZQ%A-990D=
MC6E2;EJ\EF)3B1)2]V=H9N^GW*J9=SM4S)QY1,(>6?;NUZ%\9\!XGA5,VJKI
M3*^]EH#ILP%6.ZD-:H:T?(GQCS4Y5]PN8YW5.I*.=,H;(UQVRI9`#@A`<YWU
M.)'>4\`8:U``(F5(H%*D0!V3```@;]1$2@&PCO\`2/74_P"_;);)T%.SHT``
M`#X17G<]\XS7$F<\ZDE25[R8].X@@`[C\&Y1'<3`7;<1#Z0#;^[6UE9*=T+F
MC_"/[(S;+J)#R2&N;V:Z>';`/:.X`/<`%Z@(?PCTZ@(;;".M3IDR=,,N6'.(
M[2`!^P1CM*";4.&X]QUBU7<P?$4AQ'<#`8NXG(<HIJ$$.TP'`4Q$.TWPB&X:
MQ,O<LB?+:&G0]"J]_A"RQ+:KY#W;A^[4??V]8G*>QAGRS9GX3Q]?M\BZEIW"
M5RE,6H23U4ZSEW6&C&.FJF*RRICK*"QBY3TA1.83>6V+U'7F#[CL/I<7Y*>Z
MG8V7+JI8F`!44@[BG34Z_%8]6/:_EM9D_&[16S'3'T<STU<A(:N@Z=@6'G?-
MZ?")3#N`"&X`'^/B.H'5JZ@I\#%CV/DN)<7C;V0=P['^+P`=_E^#<-PV';ZM
M:][73-H4#I\^L9-;L!>YVYI*CX#LAO\`Y2^XOA7B5E7%F&;_`!F0+%?<O)L5
M*M$T:"CYD$PD;&UJS$)51[*1GI#O95R()@0%!\I,YMNFI$Q?C'(LVL5;?;.^
M3*H:#28Z8X-Z([R`_4[;V>,1=G/+N-8#?J*P71DV;6W!/2;+!<0I34`'2%^`
MN(E)N)B&,(=Y1[>\@[?*(!N`B(].FX:CIFG1Q<2XM"C16JJ(!W&),,QA87.)
M:0&N0?5JFAZ]\>PG,&P;_O\`F_NZ#K<03JU(R,R7T>K7]T6]Q@'YPZ].TVP=
M?L#H._36MN[>0\.3PZ1BZ8X:,+?FJ_M'[(J8^VPB<`#Z?E\?^6L7F9N1$E=_
M;&1>T-!<4<OV^$6"J.XB!PZ;AL)B[=/M^@=M(KT.CMR^4:>;[HUF;+,U0\>D
MFO@8]`.&P#W^.WTEV_8/@([:V+-V`[//VA>D;"YA:`':=_?^Z+1/L(_>]!'<
MH!V^'7P'ZATK6.#RXJ00$'=!Z@EG=-T8=!_;\X!.(=?,#;??^$?AV-](=-NG
MCI`7(0X`/[`80>0%Q)<T]$UU^4!U#`7H8.X`#H.WT[=1Z?0&L6MGN*/`:WO'
M]\*7RV;3-)`2+BF^'J??PZB)1WW\/E`/'2N9,>5U8.X)^]8&!&:.W>)_\DB[
MN^'?O+\VW=TV\?#6S;V:]/G&*G:NX*O7L^$!R]#&\=@$=OKV#P_;MK!S=S2T
M=2$C8YVQI=U0+"#.?7.C'/!?#JU_M1$K!>)X7D1B_'C=VFC)6ZQD0W,HN;8R
MC&MP@""T@[[1!-,`(0#*'*&I#XSXXNO)>22+);3LI&ZSYA:2UC&@DZ]-Q0[0
M=%Z^,8<H<GVWC'%)]WN;@;B\)(DAP#WN=H"!U0$ZE/A$9AQQ*N/+R)A.;GN&
M<W\68'@LO^:OCIHY?L+1,!7RF57:PM;@TIAK$U2#B"CV&9)^>[)MWNQ(H.PW
M!MO)-'QU,=@'%&/UE;>J)I$Z8UA`+E)<YSMBN4:KH$34I%*JCCNKY*IV\B<J
MY#1T%MKG+)E/<'$`>1H#0Y&G3^'Q3583E[@'MEO.&%&QGF6F9AA<X87RF\)&
MP%J8101$BV>OXPTW#KJD:R$G%R4/-QZ2ATG22A3$,3M,780'3\XKYL_Y$N-9
M9;C;YM%?Z)FZ:'/!:?.&$`;000XA5B/N8^$O^-K50WVWUTFML5=,VRW-:05V
M%^NI!!`*)#61BB43;=1*([=`V-MX=!WZ#J=RXM:'CKV173<#Y>R'I\">T&3,
M'#.M\MK5R-JF&&-F<NGQ65[AT6-,AJ8TLRT.I./[$:61>+O%V+-9PW:)IE]0
MJ)$]^N^JQ9G[AKE:LVF859K3-KJF6=I=*>-Q=LWZ2]I*#0$KI]10"+7X=[<:
M.^X-*SF\7F30V]Y7^;+<=`47<'-ZZ]AZ1T/(WLY8WE.,-OY%<0^6L7R/)CV*
MDYBQ1K6&B$HJ62K[7UEDCX)]%2#IU#S3!B4ZY6SM+[Y,H``@)@'7#L/N.R6A
MS*FQO+[5,H95;,:V67/0MW%`7`MU4I])TCMW[VUX]68?49+A]YD5[:2673`R
M6Y"FI`.Y=/$=D,*D.50I#D-OY@`8OUB!R]Z?3_Q!^[5MO+,F>K3[G39FW5=!
MT<J?)(I^)ADK3S0/3ED]FI_"?L5?E$MGVB+.XXH>UER%Y13T:5XT"V9`R'!Q
M;HRC1"<0IL%%5.+;BY(4RGI9BQ,E&X*$*(@`;@`]->?7N`']><U46-4Y+9[?
M2DN1"4?]3@!_"WS?*/1SVXU/]!\&W'*ZQO\`V_JS)K`=-P9]/7^)R-^<?/HO
MO/<VLY8MF;;@7@(XN4I69)Z%JM44]LT_C^(B&S1)T#9FHDC'2,U8"@"AETFZ
MA@0(!=RB8=M+>_;]@&-W&3;[SDDME9-?L])S`UP)*!Q.[4'1`@^,:Z3W)<C9
M-:WW#&\9<ZCE-WF;N+FD`:@!-$\3\H<!]L'W,4^?,'D&"M5*98ZRUC$T6ZG8
MJ+>/'<!.0<P=RS:SD.2232DV1VDFT.W=-EA.=(_8.^QPVC7F;B'_`(NGTSJ.
MJ%9:JN7NES=I:&NZAJJ=V[J.FD2SPAS(>5J2=3U]-^4O=$XB:S<"'!3T'5I"
MA>H52$Z0QWSFS2O9?>J@IB-Q[<,TI\?)&@U^OXRI+([Z>M%EI,$M;3Q;$H)K
MHM&1KE,I"]='(<B"!!,("(!JQ'&V-R:?V_S)%764]`;L'F9/F-*,\Q\R;FJ=
MC4`758JYRCDU76^Y&56T-)-N#;2YH%/+<%<C=B;MK@/.=QT[".L+=K7O#\OZ
M/RYQ?@3E7Q5J^(X'*-AJT6SB&KV;/=(2+NTJI$0=D3DW,@^B)UNWD1['"0(M
MS@)#`':(;:CFHX$PV[8-49#@]V?6U-"7>H7#R%S02[:``6@ZD*3H1UB4)/N(
MSNV<ATF,9C:)='2UCP&M!.\,F:,4JA(5O8A0](=PYU\M+#Q'Q9%7"HX2O><K
M;:;2PIE7K509KK1S2<E!$D<XM<BS;/G<='.'`@DB"2"IUUQ!/X?'4'<?X)29
MY?\`\E<ZZ1;:"5++WS)K@`0/X6DM4_/3JABP?)V=5F#V5M5:K?47&[3GAC)<
MII*$]I(!0?8O?#,V5_=>]ROBG,X_M?*OB5BZJ8RO\FL@RBV$A*IV,C=B5%Y+
MQZ,NVLLT@SL3*,<%4!)ZT(43%$NP#OM/M@X8XGS:FJ[=A=ZJ)V044J8^84_E
M$,/E(!:%#@A4.37K%<;QSMS'@%11U.?661)LU;-8V6>DSSZH?-U:J$%H.FHA
MWGGCS&=\5^'$KR4J$-$SD\Z2HB=,@;.+I&/>O[P[8@U0D$V*R3L3-HUPJH8J
M9^X!3$?`-0CQWA+<QSYF'W#>*/?,;-=+ZMV*-RH1MW(.G:(G?E#D>9A'')S2
MB](U<ULOT@\>4F8-Z(H*AH/;#9W$?W8N5/,/+7'['-"P'#LJL^ESDY(Y;:5F
MVR%.KB:",K)+0-7<J.C,(H?PUJV:^K>N%5%W:HB1,A0V&5<]X1Q#`;'7W"ON
MWK7=CRVCIVD-<0#U>JDD@=@`$11QWSSF7(E\M]MMULERK698-54.8XLW$#Z4
M(VZGM)Z1\*X>[_RJ?\S<T<:N/O'.K9TCZ7.66F4&-@TY]&P/IR"!FQ7L]NG0
MD3P["JQLH#CS]D6X'`I"@J4=Q'[J?@7$Z/`:'+LINDRWU-3(9.>'HX%K@#L:
M-/,01KKJND<RJ]Q&?3N2;AAV+6N3<Z61/?)9Z8+=I:2-QU*@$'33XQRBL>\3
MSQP[R1F\"<G>-<%<;FLU*TA\58JCC,[HVL\S&$E:<SBI)O.V"-FX20(H7U!S
M?>IH=RH?(8-=RH]N''F1X9_6F)72=*M<J4'S)LX[F^5P;,`",(*JB]/&&];?
M<ER?8,VFXAFMKDS;C-<6R9,L%K@XZL75RA.NGS"Q?D;W6_<KX_\`(_$-1Y&8
M'QECVIY2EZZNQQFW;*2DZM59VQH5]THTMK"?D5$9R+7<%W(J@0!5)L*?:/3&
MQ\(\4Y5B-;=,7N=1.KJ``3)SM&;BQSB`PM!Z@:J01T@NW//,F'YE26S*K=3T
M]#6S/Y<D!7['.`'F4]%UT^R'V>:_(;)O&;"#O(.*<'6G/UW<S<96XJJUE!11
MO&N9M8[5E8+*@Q\V74@V[H4TCD9I&4,HJ7N,F3N4+6K!L:L>69$VVWZX,MEL
M(<YTU_F`#"%:T`C4A2">[H8M;R!E%YQ7&772P6Z9<[LYS6MEL*(7@D..AT!0
M$??#%W(3W`_>'X=QE(S)R'QC@6)QG=K#^'M*7',T'3]HY]&K*?EF6>1T^[F(
MB24CFJP@MW.2D.02FZ[AJRV-\8>W_.C5V?"J^Y3KO3RG/$QYVL<&Z*`98[>Q
M8JWE'+WN`P%E-?,SH*&5:*B<&>F$WJ=>N\IIX=L21?ZC?_1_]7/PT=OZ8?U(
M_!O/_A_*GYH_"?5^7\NWW/F=OAUVU4S]+E_K/Z-ZCD_.>CN[5]3;_P"!UBWW
MZY,_I3^I-DO?^G_F=OX?]+U$5?OZ=L;9>;I7,>T^UWFWRJ$-5J=7I:RV&4<*
M`FDQAX9@L_?N!-N!NXC=$W:`?$8VP!N(@&M=OH*JZ7"1;*)I?6U$ULN6T:ES
MG%``/V]PCH76[45DME1>:][645+*=,>XD``-&[4G37H.^(`.><NYK]U#FHQ+
M76+A_(9$L?Y%PS37;H[>.I%&;J+K,_6CU39)D8-CR<PY`O<HH8X>!4PUZ>XG
M;,4X/XW-96L_DB1OGS$2:^H(U:.I1=K4[H\F<IO&5\_<E"DI'$U3Y^R0P$F4
MR0':./8"A)5=>L+ER%QA]M3@_8Z]ACDK9LV<M.129(=LZQIC:1&G8\J$C;UV
MAT(DKDSQHLU-+NW*1RD%THZ5(<%5$2]P!J,Z'..<.0*"?D>'TM%9<89(F.;4
M/E@3)LMFX$[W':XZ$*!HD2_5X-PMQ[64^*Y=45]YRUTV6U\F4_\`ERWOVD`-
M#7$>5W0ZH=(4-[_$S7\>8BX;<6:)#?ERN1#65MC&JMEE7BD-"5J#85&M17F&
M47<.U$5I)TEN(F%0Q!$!$=,WVLR+G7WV^91<I@G39HV/F`("XS1,+B>FH3^R
M'![LI])0X[8<6MTOT:>7_-ERE5X!EE@!;UTUU[_C$95U$3+4Z+1S%2;%Z],"
M+)!_'/6!W#A11-$B:!7:")E=EUB%^'?83`'CJ[0NMNFT<RIIITJ;*IP3,+7!
MP9M"G<G3YQ1P6.Z2:Z135M/.E&H>T,WL+2X.("M4:_*)+OO(F)@3@1P4XCQQ
MP35-&0LY88\A_(%<E`IS)%T9PB!@!1)>U6<QQ[RB7O((CU#I2WV]T+\BY9R+
M,9Q$V2R<\RB=0=TT-VM)[I973\.O2+M>XZM?B?%6-X31.]%LR0QTQHT)\JZC
M_$JKVQF^UVFYXV^U?S5Y'7[>)KF0RVE*CLY$/(3GS,*6M1XYXP;J`3U1YZSR
M_I4Q(4PK>F$0$0\-/.$Z7FW.-BL%G:'5=%,;ZGIA4!?ZA)3^%FI[HZ'"+#@W
M`E_R2YO+:.K8]LH3-`21Z2!>JN.GA$>_$/'7,.7<D8XQ17Z3:&-BR;88^M0#
MN5KTM&QXJN2).9.6]2^9((*QT''(JO5SD,)2H)"(B`"`ZMG?<TQ_$,=K:UM;
M3/G4-,-P$QI(?HW:0"3N4HG6*BX[@U^R;)*.W&BJA+N$XEA])R.:\E7-*:M:
MTEY(Z`$]!$K3W=&5>XA>U72N-M&6%"*E9K'&)612?<N9.*KP+7"U2BX%[3*+
M2KV$\Y8?`3+COTU1;@NIFYMSA/S*X>=S63YA!UV[FEK`/\((0]PTB^/N%IZ?
MCW@>DPFWHWU'2I&X$!2P^HXG_$YJ?-(6=P,85#B1[8N(;)>9!C7HFL8;>9;N
MC]RNDV;G<6E)_<UB'44$OJ';DKU)LD4=S*G$I"@(B`:87(=3<,YY@JJ>C:^9
M63*L4[&,!<0UA#=^T*4T+E[!$G\9-M&!<*4=77.DRZ1U`9SW/1K2Y[2=I)[2
MH:!U6&JOT_53D9&X\P.4DFR4B*;+G)78YPHGY+-=ZM-2V0K$@B':!#!!,%V9
M5!*/P^8!1`!#4Q^YVJ:RSX]@`(F7-K);GH5>US6AK6N'4%P*A?"(%]KEOGRK
MED>?N:X6M\R>6(#M<T/).T]H"'IH(Q/9(:*YZYQ\TN5\RCYQ#J3R$0_5`3E;
MR&3[N_E$P;J*`/EJ-JO744B["`^6IMX:V^XJL98^-\:Q*4'RYCZ>7,<P*"W9
M*V><=FK@=>IUC7[9:9^1<IY)FT]HF,=,F,8XA1YIH<`#W[0?DL8F1$D^4?Z@
MFFUPHED*W@1:O(N4S!YZ"(8HJ+JV/P/V@)"]]RFBIF`?`VV_77TV:;_1OM6J
M:@'TJZX3M'#1[]SBWXGR#L[!&=X]#-/=C(IV#U:6WL&\=6L,M@^P[A]L*WY0
M>X1R7ROR^=\!.`414(R^UXSI+(N9KR@A)1]8<1+1!Y8B03!9%W'MF];2=D(N
MY5;NUU7B@)()@(=VF#B/%F)V7!V\J<D.GS*&8X"GD2SM]0DE`[0DAP!T"!.I
MA_9SRWF>0Y^[BSC.7)9=)8/KU#V[_33J1J`W:>A/;#._/##7)!7EOQNXOYVY
M8S?**\W>6J#N69),RL*SC>0N5L;P;B,A(=)?RDGKV$9*+*G4;ME/(`@B0"CJ
M=N/\CQT\=WS+<7LDJR2A+]-LQ$]1H:BAY^HDJH4ZK%;N4<>REW(MAP[++V^]
M5OJATP`KZ9+MP:6!2U!]WA#D'ZAZYGB\2<7..585,1Q:+F[FB1R1]O.9U"+9
M5*MHBFGL/8:5L0"7<.WO3Z=0U&GM7I*D7J\YC-],TM/2S&O+NNYS@[0GMTB9
M?=?6T\NQV+`:8?\`<SYTLM[&[&M]/4=O5(>WQ;3Z9Q'XF0,-'Q416X+$&&0E
MIE)@W09MW,I`5,)&P2[TJ92&6D9.3055654$3G.H.X^&U=KI<*C,\^F&;-?,
M?77!)0<5(8^:@:U>P`]!XZ18VQ4%/@W&K)#9=/)%);09CP`%>V4JN/B[M/72
M&*?T]%2=72T\N^34V4ZLC;;'$55N_<`<%%7,R^D[]92%,<`$`%:19@H`#_"7
M?5A?=',=;Z6QX;3O)DT](U1W%C6-`/BA((BLWM(HIEPN%^S6M+?6FU+D.AU<
M7.<0>[32-&X$.!Y3>]ER1SPLD61@<7!D=U#NE?O$VR+=PUQ54RHAU*"GI4':
MA!`=@#<0^G72Y-J96*>WBSXS03'2:JH<PN:TZS&O:9DPD=H#T7L!01\'%$FI
MS?W&WC)*P,GT5'+G!I(4,F,FM9+:#T#MJD#J@)[(]N48ARB]^;!^*@`SRMX7
M4H2+YML"S='\FQK_`"I8P53W$I!/(.&Z)Q$=_E`>HZ^G!I%-B7MHNMY>[TZZ
MLW"404,QP<9;2.]&QKSEM7G7N@M]H^JBHQ+]0'7TP&!S_AY]/B85IS)Y[<F<
MD<RXSV[^#,A6Z3>0.+3(>8[,U0?JP;M*!"QS#6`;NV[MLBWK<(9,SE;T[ARN
MY/Y*()]HGTP,#XUQ"U<?3.5>1A/J+>)NV332?K<7;DW#4D.('5`A&L2+R'RM
ME]RY#E\4\9.D2KHUG\Z=,U#414Z!6@GO*B&:/<CP1DVK9SX^\<[MS(OW+C)^
M09:+"UL)J5*:NX^F[398NKQ+"&@$)>4"*DY)!=TH;SBI+"W*00*`#JPW#.26
M&?C%ZR218Z:SVBEE$,>UNU\S3J7:`H=-%[5,5UY?QB[2<VLV,5U^FWRNJIK7
M3&.<"QA!&B`Z:=.FB1-<_(D=_2S^F.QOPC\C_D+;N^/\,_`?RYW=V_S^E^+?
M?QUYZ?J%1^K?JFT>I^<]7_+ZFY?BD>C7Z1)_IC]!V#T?R/H;>Q/3V(O=X]T,
MY>_KGB1Q;PW9XV@W1FDIG^[L:6]52.)%@I\`V&SV9$IB@!BDD#L&K50=P`4U
MS!UWVU8+VN8M+R#D1]RK0'2+9)=-:$57N:0P^".Z>,5[]UF8.Q[CIMHI#MG7
M2;Z3C_T-(+OM&D13^#7)]'AYR>QQGQW5#76-JHS\;,UUNX29R+F&LL([A)!U
M#.EP%LE+L$77FH`KLFH)1*(EWW"\?+.#5'(&!S<>I'^A5N>'#X@AVHTTTB@_
M$&;T_'&<2L@JV>M2L;M*%-""-"AU[H=;RE[G?MVS/(9ER<JW!JQWO,,I.5N1
MM5PRC9HULRBDX-NS9GEZY2VLQ8()U;VT4R3(@LJ#9)-4A5#"(AOJO5FX,Y7I
ML8&,7#(6TMC;+>QDF6-Q1SG.(+CL(!<XD@`Z'K%@[_SMP_494,OEXY-JL@F3
M&/?-<\AJL:UC7!NP@D-:`"O4:B$M<L/<6H7)_G)@7DY(XUN+3%6'$:7ZC'$I
M)0*MBEE:Q87]F?BW?('7AB(2$@N@!M^O:F(#OOTD#`N%KUAW&=QQ"DK&&[7"
M:\LJ`"$W;>HW+V$J'#K#`Y!YDQW,^4+?F<RCFBVT<M@?(<[=N#5T'E&I)[CI
M\(Z7E[DW">ZI[AW$&+JN/9;'E-CK#4JDM6I9W&/7RR3>VK7.XS*Z\*FFV]*>
M*C2HAN7N`"#N.QM<VTX-=>"^',AFY%5_FJVH#]G?YFM8UHU/;]T=V^9I:>;>
M7\=EX[1&FMTF9*#FZ#1K][E1K1T5-.D.9^YOSQXCU#DZZX[\J>)D=R)I^-ZC
M5IZOV&*D6;>UU:SW!HH]DX,6T@ZC4G$.^BD6(G*F[3ZB/F)G#;:".(.*\[O6
M)_U7B]W_`$V943RTL<-"`44ZA""O85"?*;N9^4^/K=F8PW.;0VX6VFD,?)F-
M<0YC@`[:4!T73KXPS=S,]S23Y5-<784HF)4\,<6<>62K.8["M1>-GL[;2PD@
MT".C)%5DP;1B((H`=*/CVB1TB.5_,.*QRE'5A\,X/H,+9<,AOES%7E]=)F>K
M5N0-D*TM!8KBA+0U3N"JB((KOF_.=3F]5;L=L-M%'A5%.9Z=(U7&<A!\Y`"J
M5_#IWDDF)GV%&9\LU'#V9,BX7<8BOD)6Y4*K19Z893TWCV'M#)BR51>+QC5E
M'L9Z2A6**:R:93G:)G.CWCW'UY]7KUK17U]IHZ]U=23*C^9-_#-+7DJ-2H!U
M&I4ZJ8](,7H:.ZVFVWZX6]M'7R)(]&7^*6US=O<-=IZ((8!]_F>>93SQPTXI
MPS@RCR?DG$X_:H)BJHD_OEFAZ)"N5$@$I!,V8MWBI2CXDW\`W'5I_;%04]JL
M609Y4@"71TSPU>A<R7O`^;BGC%3_`'85AO>28_@5.\GUJAA>!U;ZC]J_857L
MZQT::]DKE!9F#'!]H]P*V2_%*(?-%(BB/8*=>3K*)9+E7:17X:>8)65E(\Q-
MFRJRBS9(=C%;!L`:X,KW`XA(9,OM+B\AN:SFE:H/`&XC4H&ER?.'#.]L^75-
M-(LU7E,P8?*>#^5+%5HUV@[P%^4/,5/B;2</\49WBYQ_.3'L:\HEJJ\199!L
MI-2"-@M<4[CY&ZSQ2+,G$Y-.7+L7"X@HD*A@[2B4H``5^O&8W2_Y<S+,@8:B
MI]=CR`4`:Q`UHZH`T)JI[XL';,)M=CPE^"XX_P#*R#3OEAY"DF8I<[J%4N/A
M]D<(]M#V^B>W[C"_4EW?&62IZ_7%K97UC:5M>L(IL(N&;Q,3#E8KRDLH86HD
M65%0%2@8RP_"&VXNOEGDL<D7BEK?RKJ6FI:02P"X.5-HU0)V=(;7#G%LWBBS
M5-JF5;)]74U1F;PU.H<G;XQHG%#VS)'CWS)S;S"N686>1K%EK\Z&C8!O2CUL
M:NI=+.A-/3_B9Y^3"2]-&-$F1=D41$I1-OU[=?1F7+IRK#+?@5-3?EJ.C#"'
M`KNV-0'IVK')P?AF9AO(-QSVLN`J:FN+_+L1`\KU4]/"$TY=]F')4ERSOG)S
MCOS`G\#/\DS,Q.RY8ZGOG]G@%;04H6>-A9N-L48V?1$FJ'G%2=)`9(X[=QM@
M$'MCG/=BI<(EX5E=@;<A3@>D]S]LM6_22TM(T\#\(:%_]N]\J\\GYMBM_-L-
M43ZC`Q7H[J`[>/O$;#AGV183$O+#&W)U]R2N^3'E&F&EKF8W(=:))6&XW%"'
M?,5IV0MOX^)D">N>>H01],IZ<I`3[C?-KGWWW!SLAPFJP7]*DTK9A'GE.+6!
MH^D-:1JC4!UZ]@CZ\9]M5-C.;TV:S;M-K9L@EQ$UH+BYWU>8.Z*J::!-3"B.
M87MEH\O^4.#<_P!BS&ZKU6PL2ME0QDWJ*,FA8#PUQ"VR0.)]6<;'9$FCHHHF
M`C8PD!(!'N#IIM<?\LOP#%KEC5%1[JFX.),TO0`%NW0;2O4'0P[^0>()'(N7
M6[)JJK`IK>T`2@W50X.553L(U$+HY'XA?9VP3E3#47;UJ$ZR94)6G_F]M&$F
M'$&UF2`W>N$8U1VP3=*'8F42`!5)MW`._34=8O>96-Y'29#.E">:2;ZH:2BD
M$D:H40H>G9$EY=C[<IQ>LQR3,]$5,GT]P"ITU3MZ=(3MP8X,Q7!_CY/X2K&0
M7EODY^R6NU.KY(P#6'>%DI]@WC([MAVS]VD9"!;,T@)]^'F]H[[;Z=7(?)-7
MR3E$O*ZR3Z4MI:?14D(%)Z@?5VZ=D,OC3C*GXSPZ;B])5";53@XNF[4U<"%3
M<>BKUCFWMX>VG!<"I;+EF+E>5RU9,LK1`2$O*U9G6U(UO&NY62<(HD:RDGZD
M9"2E3JG,(D`!*&P#XZZ?)'+-5R12VZWBD924EMEN:`"3NW!H7HU/IZ:HL<GB
MWAZEXQKKE=9E6ZKJ[G,W$ANT-4EW>==>O[(Q\(^V5"XBYQY3YORV7IF\V?(J
MMT695%[58^*CJP:XJQR7_IY1"3=.)$(J%CO1I=Z1.\B@F'J`!KZ<CY?KLAX]
MH>.F4LNGHJ%S';VDJ\L:6ZA`-25Z]8U8YPQ28[R56<E.JWSZFI8\;'#1H>X.
M)![P@2."\EO9:C,T\GY_E'C'D[D3`=KM[]O-6%&JP:#Z1:S98U"(?2=7L:,Y
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MC0$@N!3BW;RDQ`0TA%)K`'W8'<H0SGL$>HB0=O`=7&]GE7)DY#=9,YZ3YE/+
M+%ZHTN.GS$4D]Z-#-_IRU5LN7ND,GN#O`N0+X=8B@=P[CU#N#Q\-^HB4?MV$
M2B'U:OT][IC][RK^^/.T%S6;`H9%2F,4!*78`'?<-@VZ[;]-OL#2O>^8T,>5
M:.D:RQKBIZQ0I2[B/:&^P!]0=/#<`V`?V[ZQ;*"/FM:TN#=5[EC?+G>F6[R[
M8#T$=AX_9\R)QCRU7LRXJ4@VUZJZ4LA!O;!!M;$P9'G(Q6*>.B1CQ4J1G96:
MZA4E>@E$P@&FIFF)6W.<?=9+N9GZ=,>TO:PD:@@J"-5"#X]"(>F&YE<<+OTO
M)+3M_/RP1++@"AU")W:H1W&-AN5ISQS7Y`S%G7A97*.;\NR[%4T33J\)5Y!V
M@Q:13((V)9&%"-BV3%BF416.1)$I1,<X!UUR:"V8OQ/B?Y:9,9(QZ0-S73"C
MSVJ5(4GX1]E;.S#ES,'5WH.J;Y4O1X8#L'8A`5`/`Q*L]L/V:H7CHY@L\\FF
MD7=,Y%!%[5J644I&I8J5,'1V<R>S2PW,A1V%R8IT&0ALAWGW5&D?-WN&J<O:
M['<1]25CI0/?J'ST1=V@1H.G>4'9UOOP=[<*'$MF19?(D/OH&YLM%;*/X44G
M5$*=%)^`D!B0I>A``.X3";8/'?<VX_;WZK#YVMV2TW`*D6P(+WL)U"I\@%'V
M&$6Y#X$\<,H\EJ;RONU:GYG,=#/6S5:0&X3S>`C3591VO#F"L(N20JP-W+Y5
M4P'3'S%!`3=0#3VMG(676;&*C$Z";LLE43ZK&_B)ZDGJH0)\(CF[<887>LOE
MY7=)6^]22TL<>PL3:.G32%KB0@^)0'^T-_\`'3*+&EP<1YA$DG4(>D4\I/\`
MTAHV-WF8GG/4P$!P`=J!T@!),H[@0H#]>W72&6QS=I'E6,B]SNIBOEDWW[0W
MZ]?[?'2N:UZ;@J=(UAC0[>!YC%1(0?$H#L(#U#?J`;`/]H!I'RV3&AKPK1TC
M)4*]IBGED_TAU'?]H!M_AK(@%NT_2D8L:V626!"[KXQ4"E#?8`#?QTC6-;J!
MJ`GRA0`%3MZP=I0^@.OCK+QA`QK>@@["[`':&P>&E4JO;"H`$[$3Y=T':78`
MV#8/`/JUBYH=]7?"C0(.B0=I=MM@V\=M*=>L(&@#:.A@`I0\`#_ITT#0(.D*
MF@'8.D4!,@=`*`:1!N+_`,1@=YPCM1%VP?4'CO\`MWWW_?I8%A*_,CBE1N9&
M`[GA"]K'CT9Q)"2K5E:($5D:A;X@QG,!96!3G*"BK)R)B+)]Q07:JJ)"(`?<
M'=A.95."9'39'3`NE4[EF2P4WRU5[50HHZ%"A[PHAD<BX52<@XI58W5;6S9K
M#Z3RW=Z<Q/(Y%!(#NJ$:1!!Y/^WSRIXF6.1B<CXRGIBLMG#@(G)5(BWUCH4X
MR\[X)!.1CFRJL"=5,0.LV>IHJ(*&$-A#8P^E>#<V8+G-*R925+:>O?\`[4TA
MI7XE%'B`D>5&>\*YQ@MP?35E+,GT+3I.E-<YI"=P77LZPBQ0#IG,F9,_<41*
M8/+6$0,'02]$O$!U*,VNI9.LRHI`/_>;\>Z(L-!4&:93&3%'8YI:[YMU2.N8
MUP%G7,<BC%8JPUD[(#UP<I$0K%,G7S0W=L'>>4,S2BD$R"/4RBQ"A]>FQ>\V
MPZTT_K7JY4DB1JB36DE!J$4+#GQW!<PR"M_*6&AFU4Y!N#6DH"4!=IH%T7Y0
M])QA_3^\BLD.X^:Y&66%P343*(K.ZW%+,+ADN1:;B91$$&YU*U7E%0V#S%UW
M9T_I1WU7K-?=ACMNE.MN$RWUE4P$"8[R,:\='(A+P"AT(!`ZQ9O!O9]E%PJ&
M7#-:B714.X'TV#U'D:>5=S=A1=2"0J^$2?.+'!CCAPZKAH/"=%:14H^1(2PW
MF8[)F^VA0I2%,>9LSE,'HMS"0-FR'DM2!T!/IJG.;<CYAR%6?F\HJWS@/I8U
M6RV_!JE?FI\4B\>"\;XEQU1?E,9IFRWGK,>CGGYH(5T0@E*`";<>HB([_2._
MTB([!IC$N/=]D/IK`.JF+NW[=MOL_P`](6AQ#G=08R&G3I%!)OMU'IL/[AUD
M%#R[O$9;NT(L7Z(Q@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T01:;
MY3>'RCX^'A]/V:(4=8^.]_D7>WX=_+!_/?[=\@_SG=T]/_GK[)'^JW_4^H_1
M]?\`E\8^6I_^N[_03_K^G_-VPE]YW>K<?_DK_NG_`)SR_5^(_P`Q_P";]>G,
MY?3U_6O\W3[H;$E=VGZ2B_@3]^J]_C"BJM_LC7?\L_*7_P")?['X?^W[.OE_
M5]FFY7?ZG^]]/^[]7]T.&AW;C]'_`,6W[XV?^(/E^8OR_/\`P^/_`!X:Y`Z:
M*B_@_>OWQ]KOJ\?OC)U]$90:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T0
/0:((-$$&B"#1!!H@C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
